Biogen By Buying Nightstar Targets Ophthalmology As Emerging Growth Area
Biogen is paying around $800m cash to buy UK-based Nightstar Therapeutics, which focuses on gene therapy for retinal diseases.
You may also be interested in...
Therapeutic areas and unmet needs drive big company decision-making about when and what technologies to bring in from external sources, executives explained during a panel at the 2020 Cell and Gene Therapy Meeting on the Mesa.
Biogen will pay Denali $560m up front plus a $465m equity investment in exchange for co-development and co-commercialization rights to clinical-stage LRRK2 inhibitors for Parkinson's disease.
Japanese company joins the ranks of big pharma buying up gene therapy pioneers